Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146.

Publication Title

European urology

Authors

Chung-Han Lee
Amishi Yogesh Shah
Arpit Rao
Matthew H Taylor, Division of Hematology and Oncology, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA.Follow
Christopher Di Simone
James J Hsieh
Alvaro Pinto
Regina Gironés Sarrió
Allen Lee Cohn
Mehmet Asim Bilen
Sara Gunnestad Ribe
Øyvind Krohn Tennøe
Donald Richards
Randy F Sweis
Jay Courtright
Daniel Heinrich
Rodolfo Perini
Peter Kubiak
Daena Bock
Chinyere E Okpara
Robert J Motzer

Document Type

Article

Publication Date

5-21-2024

Keywords

oregon; chiles

Clinical Institute

Cancer

Specialty

Oncology

Recommended Citation

Lee, Chung-Han; Yogesh Shah, Amishi; Rao, Arpit; Taylor, Matthew H; Di Simone, Christopher; Hsieh, James J; Pinto, Alvaro; Gironés Sarrió, Regina; Lee Cohn, Allen; Asim Bilen, Mehmet; Gunnestad Ribe, Sara; Krohn Tennøe, Øyvind; Richards, Donald; Sweis, Randy F; Courtright, Jay; Heinrich, Daniel; Perini, Rodolfo; Kubiak, Peter; Bock, Daena; Okpara, Chinyere E; and Motzer, Robert J, "Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146." (2024). Articles, Abstracts, and Reports. 8835.
https://digitalcommons.providence.org/publications/8835